GlassScriptPhysician profile
Leoncio S Dizon
NPI 1114982352
$17,182.88
in general payments reported to CMS, 2019-2025
54 companies · $2,444 in 2025
The $2,444 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,177 · 2020: $1,722 · 2021: $3,178 · 2022: $2,423 · 2023: $2,735 · 2024: $2,505 · 2025: $2,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,683.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,157.62 | 2019-2025 | Evenity, Repatha, Prolia |
| Abbvie INC. | $1,897.04 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,876.86 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,805.40 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Astrazeneca Pharmaceuticals LP | $1,374.94 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $904.40 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $753.68 | 2019-2025 | Spravato, Xarelto |
| Pfizer INC. | $535.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $485.95 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $417.94 | 2019-2024 | Veozah, Myrbetriq |
| Neurocrine Biosciences, INC. | $407.51 | 2023-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $390.81 | 2019-2024 | |
| Exact Sciences Corporation | $288.76 | 2023-2025 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $283.50 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $272.24 | 2024-2025 | Caplyta |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leoncio Dizon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.